Can-Fite BioPharma Ltd. (CANF): Stock Price

Can-Fite BioPharma (CANF) develops anti-tumor agents leveraging patent protection for pancreatic and liver cancer drugs, which restricts competitor access. Orphan drug status and stringent FDA oversight create financial barriers for smaller players. The current metric stands at 1.67. The price history on the chart below demonstrates the market dynamics of the company developing a wide range of oncological drugs.

Share Price: Can-Fite (CANF) for 07/04/2022 - 11/11/2026

CANF (Can-Fite BioPharma Ltd): analytical breakdowns and indicator data

- stock quotes and analyst forecast:

Stock Price Can-Fite BioPharma|CANF - Consensus Target

- stock exchange capitalization data:

Market Capitalization Can-Fite BioPharma Ltd|CANF - Enterprise Value

- book capitalization information:

Net Assets per Single Share Can-Fite BioPharma|CANF - Accounting Capitalization|Market Capitalization to Book Value Ratio canfite.com|CANF - Total Asset Value of Company

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

CANF - Final Profit|Projected Future Earnings Can-Fite BioPharma|CANF - P/E Multiple|Future Price to Earnings Can-Fite BioPharma Ltd.|CANF - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Can-Fite BioPharma Ltd|CANF - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Can-Fite BioPharma|CANF - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months canfite.com|CANF - Earnings per share growth this year|Earnings growth forecast for next year Can-Fite BioPharma

Analysis of all company metrics:CANF Can-Fite BioPharma

The price action of Can-Fite BioPharma (CANF) reflects market expectations regarding the commercial success of piclanideson in the treatment of oncological diseases and psoriasis. This indicator synthesizes aggregate business valuations, where the final quote is formed as a balance between current Phase III clinical trial risks and the company's potential for future expansion in the global pharmaceutical market.

Who Can-Fite BioPharma competes with